Volume Alert - ABT 44.09 Abbott Laboratories $ABT Hit a high today of 44.10 Closing the day 11/10/14 at 44.09 +0.72 +1.66% With a day low of 43.17 and a total volume of 5,327,053.
ABT Recent Posts: http://investorshangout.com/Abbott-Laboratories-ABT-49973/
ABT Abbott Laboratories Recent Headline News
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.66% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:03PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.17 to a high of $44.10. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $43.99 on volume of 5.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 44.09 (+0.72)
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.09 (+0.72), JNJ: 108.82 (+0.62), DXCM: 53.50 (+2.57), MDT: 68.71 (+0.61)
Abbott Looks Overvalued On A Fundamental Basis
Stock Traders Daily - at Seeking Alpha - Fri Nov 07, 9:51AM CST
ABT: 44.09 (+0.72)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 44.09 (+0.72), GILD: 107.02 (+0.57), ABBV: 63.79 (+2.29)
Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 44.09 (+0.72), A: 41.53 (+0.60), CPHD: 52.80 (+1.11), DHR: 81.29 (+0.10), PKI: 44.02 (+0.21)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 14.96 (+0.17), ABT: 44.09 (+0.72), A: 41.53 (+0.60), DHR: 81.29 (+0.10), PKI: 44.02 (+0.21), OSUR: 9.17 (+0.19)
Abbott to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Tue Nov 04, 8:00AM CST
Abbott (NYSE: ABT) will participate in the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company beginning at 12 p.m. Central time.
ABT: 44.09 (+0.72)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 44.09 (+0.72), BIIB: 327.87 (+7.12), AMGN: 163.09 (+2.84)
Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 44.09 (+0.72), SHPG: 200.98 (+2.40), MYL: 53.95 (+0.84), ABBV: 63.79 (+2.29)
Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien
PR Newswire - Fri Oct 31, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Covidien PLC (NYSE: COV). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 30, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ Composite closed at 4,566.14, up 0.37%. The S&P 500 finished the session 0.62% higher at 1,994.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index gaining 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
ABT: 44.09 (+0.72), MDT: 68.71 (+0.61), COV: 93.64 (+1.56), RMD: 51.02 (-0.12), HOLX: 26.55 (+0.34)
Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 93.23 (+2.17), ABT: 44.09 (+0.72), ACT: 245.73 (-0.18), MYL: 53.95 (+0.84)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 44.09 (+0.72), WMGI: 27.97 (+0.02), CFN: 57.52 (+0.24), UTHR: 125.17 (+0.96), RCPT: 109.47 (+0.23), WMGIZ: 4.36 (+0.05)
Global Continuous Glucose Monitoring Market 2014-2018: Emerging Artificial Pancreas Technology
M2 - Fri Oct 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zk3lqw/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring Market 2014-2018" report to their offering. The Global Continuous Glucose Monitoring market to grow at a CAGR of 14.74% over the period 2013-2018 Continuous glucose monitoring is the measurement of glucose levels at regular intervals from a diabetic patient. Continuous glucose monitoring systems allow to gain insight into the trends of glucose levels between fingersticks, resulting in improved glucose control. Continuous glucose monitoring system comprises of a glucose sensor that is placed subcutaneously to provide the reading of glucose levels in tissue fluid. A transmitter sends information about the glucose levels using radio waves from the sensor to a receiver display. Continuous glucose monitoring system also offers additional information about HbA1C levels and fructosamine levels. The report covers the present scenario and the growth prospects of the Global Continuous Glucose Monitoring market for the period 2014-2018. In terms of component, the Global Continuous Glucose Monitoring market is divided into three segments: Transmitters and Receivers, Glucose Sensors, and Insulin Pumps. One key trend emerging in the market is the use of artificial pancreas technology in continuous glucose monitoring systems. The artificial pancreas is a closed-loop insulin delivery system that mimics the functions of a healthy pancreas in the human body by continuously monitoring glucose levels and automatically adjusting insulin delivery with minimal or no patient interaction. According to the report, one of the main drivers in this market is the rise in the incidence of diabetes across the population worldwide. Diabetes is also a cause of co-morbidities such as heart disease, stroke, kidney disease, blindness, and other debilitating diseases. The demand for continuous glucose monitoring has increased as diabetics look for ways to gain control over their glucose levels and manage them better. Further, the report states that one of the major challenges in the market is the presence of alternative methods of glucose monitoring. Blood glucose meters, test strips, and lancets, which are widely used in glucose monitoring products, can pose a hindrance to the adoption and growth in the popularity of continuous glucose monitoring systems. Key Vendors - Abbott Laboratories - Dexcom - Medtronic Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zk...continuous
ABT: 44.09 (+0.72), MDT: 68.71 (+0.61)
Strata Decision Technology is Named Winner of 13th Annual Chicago Innovation Award
PR Newswire - Thu Oct 30, 8:55PM CDT
Strata Decision Technology (Strata Decision) has been named one of the winners of the 13th annual Chicago Innovation Awards. The Company's cloud-based financial analytics and performance platform, StrataJazz®, is leveraged for financial planning, decision support, and continuous cost improvement by over 1,000 hospitals in the U.S.
ABT: 44.09 (+0.72)
Global Coagulation Testing Market 2014-2018 - Increase in Prevalence of CVD
M2 - Thu Oct 30, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdcwwv/global) has announced the addition of the "Global Coagulation Testing Market 2014-2018" report to their offering. Coagulation tests help in measuring the clotting ability of blood. Clotting is the process of blood converting from liquid into gel form. Coagulation tests are performed to analyze clotting disorders such as hemorrhage and thrombosis. Coagulation tests include complete blood count, factor V assay, fibrinogen level, prothrombin time, platelet count, thrombin time, and bleeding time. Coagulation testing analyzers play a major role in improving patients' quality of life. An expansion of some of the economies in the APAC region is one of the main trends seen in this market. Governments in emerging countries are making efforts to improve healthcare infrastructure, which has benefited the Coagulation Testing market. According to the report, one of the major drivers in the market is the increase in the prevalence of cardiovascular disease. CVD deaths occur almost equally in men and women and it is predicted that by 2030 almost 23.6 million people will die from CVD. An increase in the prevalence of CVD has led to the development of coagulation testing products, and thus, the growth of the market. Further, the report states that one of the major challenges in the market is the high cost incurred in R&D activities. Many big vendors are facing the frequent elimination of coagulation testing analyzer products because of rapid developments with respect to the technological aspects of coagulation testing analyzers. The Global Coagulation Testing market can be segmented into the revenue generated from end- user application such as: - Point-of-Care Coagulation Testing - Home Diagnostics Key Vendors - Abbott Laboratories - Danaher - F. Hoffmann-La Roche - Sysmex Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Coagulation Testing Application - Market Landscape - Market Segmentation by Technology - Market Segmentation by Types Coagulation Tests - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/kdcwwv/global
ABT: 44.09 (+0.72), DHR: 81.29 (+0.10)
Abbott Labs Pays $250 Million for Topera in Heart Health Move
at The Street - Thu Oct 30, 8:12AM CDT
The buyer also acquired an option to purchase Advanced Cardiac Therapeutics, which is developing a novel ablation catheter.
ABT: 44.09 (+0.72), ACT: 245.73 (-0.18)
Abbott Expands Its Medical Device Business with Acquisition in Catheter-Based Electrophysiology Market
PR Newswire - Wed Oct 29, 8:30AM CDT
Abbott (NYSE: ABT) today announced that it has entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation, one of the most common heart rhythm disorders in the world. Through this acquisition, Abbott enters the catheter-based electrophysiology market, an approximately $3 billion global market that has been growing annually at double-digit rates.
ABT: 44.09 (+0.72)
The Zacks Analyst Blog Highlights:AbbVie, Mylan, Abbott Laboratories, Actavis and Mallinckrodt
PR Newswire - Wed Oct 29, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Mylan, Inc. (Nasdaq:MYL-Free Report), Abbott Laboratories (NYSE:ABT-Free Report), Actavis plc (NYSE:ACT-Free Report) and Mallinckrodt plc (NYSE:MNK-Free Report).
ABT: 44.09 (+0.72)
Upgrade Alert for Abbott Laboratories (ABT)
Comtex SmarTrend(R) - Wed Oct 29, 7:58AM CDT
Abbott Laboratories (NYSE:ABT) was upgraded from Hold to Buy at Deutsche Bank today. The stock closed yesterday at $42.50 on volume of 6.1 million shares, above average daily volume of 5.5 million. Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company's products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
ABT: 44.09 (+0.72)
ABT Recent Posts: http://investorshangout.com/Abbott-Laboratories-ABT-49973/
ABT Abbott Laboratories Recent Headline News
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.66% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:03PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.17 to a high of $44.10. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $43.99 on volume of 5.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 44.09 (+0.72)
DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:54PM CST
Following the announcement, shares of DexCom, Inc. (DXCM) shot up nearly 14.12% to close at $50.93 in the last trading session.
ABT: 44.09 (+0.72), JNJ: 108.82 (+0.62), DXCM: 53.50 (+2.57), MDT: 68.71 (+0.61)
Abbott Looks Overvalued On A Fundamental Basis
Stock Traders Daily - at Seeking Alpha - Fri Nov 07, 9:51AM CST
ABT: 44.09 (+0.72)
5 Things AbbVie Inc.'s Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Nov 06, 11:38AM CST
Another quarter for AbbVie , another blow-out. The company announced strong third-quarter results last Friday. AbbVie's storyline behind those earnings, though, is probably more important than the numbers themselves. Here are five things the...
ABT: 44.09 (+0.72), GILD: 107.02 (+0.57), ABBV: 63.79 (+2.29)
Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 44.09 (+0.72), A: 41.53 (+0.60), CPHD: 52.80 (+1.11), DHR: 81.29 (+0.10), PKI: 44.02 (+0.21)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 14.96 (+0.17), ABT: 44.09 (+0.72), A: 41.53 (+0.60), DHR: 81.29 (+0.10), PKI: 44.02 (+0.21), OSUR: 9.17 (+0.19)
Abbott to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Tue Nov 04, 8:00AM CST
Abbott (NYSE: ABT) will participate in the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company beginning at 12 p.m. Central time.
ABT: 44.09 (+0.72)
3D Bioprinting Technology Developed by RBCC Partner n3D Biosciences Helps Researchers Create a Better In Vitro Breast Cancer Model
Business Wire - Mon Nov 03, 4:30AM CST
A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
ABT: 44.09 (+0.72), BIIB: 327.87 (+7.12), AMGN: 163.09 (+2.84)
Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 44.09 (+0.72), SHPG: 200.98 (+2.40), MYL: 53.95 (+0.84), ABBV: 63.79 (+2.29)
Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien
PR Newswire - Fri Oct 31, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Covidien PLC (NYSE: COV). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 30, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ Composite closed at 4,566.14, up 0.37%. The S&P 500 finished the session 0.62% higher at 1,994.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index gaining 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
ABT: 44.09 (+0.72), MDT: 68.71 (+0.61), COV: 93.64 (+1.56), RMD: 51.02 (-0.12), HOLX: 26.55 (+0.34)
Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 93.23 (+2.17), ABT: 44.09 (+0.72), ACT: 245.73 (-0.18), MYL: 53.95 (+0.84)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 44.09 (+0.72), WMGI: 27.97 (+0.02), CFN: 57.52 (+0.24), UTHR: 125.17 (+0.96), RCPT: 109.47 (+0.23), WMGIZ: 4.36 (+0.05)
Global Continuous Glucose Monitoring Market 2014-2018: Emerging Artificial Pancreas Technology
M2 - Fri Oct 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zk3lqw/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring Market 2014-2018" report to their offering. The Global Continuous Glucose Monitoring market to grow at a CAGR of 14.74% over the period 2013-2018 Continuous glucose monitoring is the measurement of glucose levels at regular intervals from a diabetic patient. Continuous glucose monitoring systems allow to gain insight into the trends of glucose levels between fingersticks, resulting in improved glucose control. Continuous glucose monitoring system comprises of a glucose sensor that is placed subcutaneously to provide the reading of glucose levels in tissue fluid. A transmitter sends information about the glucose levels using radio waves from the sensor to a receiver display. Continuous glucose monitoring system also offers additional information about HbA1C levels and fructosamine levels. The report covers the present scenario and the growth prospects of the Global Continuous Glucose Monitoring market for the period 2014-2018. In terms of component, the Global Continuous Glucose Monitoring market is divided into three segments: Transmitters and Receivers, Glucose Sensors, and Insulin Pumps. One key trend emerging in the market is the use of artificial pancreas technology in continuous glucose monitoring systems. The artificial pancreas is a closed-loop insulin delivery system that mimics the functions of a healthy pancreas in the human body by continuously monitoring glucose levels and automatically adjusting insulin delivery with minimal or no patient interaction. According to the report, one of the main drivers in this market is the rise in the incidence of diabetes across the population worldwide. Diabetes is also a cause of co-morbidities such as heart disease, stroke, kidney disease, blindness, and other debilitating diseases. The demand for continuous glucose monitoring has increased as diabetics look for ways to gain control over their glucose levels and manage them better. Further, the report states that one of the major challenges in the market is the presence of alternative methods of glucose monitoring. Blood glucose meters, test strips, and lancets, which are widely used in glucose monitoring products, can pose a hindrance to the adoption and growth in the popularity of continuous glucose monitoring systems. Key Vendors - Abbott Laboratories - Dexcom - Medtronic Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zk...continuous
ABT: 44.09 (+0.72), MDT: 68.71 (+0.61)
Strata Decision Technology is Named Winner of 13th Annual Chicago Innovation Award
PR Newswire - Thu Oct 30, 8:55PM CDT
Strata Decision Technology (Strata Decision) has been named one of the winners of the 13th annual Chicago Innovation Awards. The Company's cloud-based financial analytics and performance platform, StrataJazz®, is leveraged for financial planning, decision support, and continuous cost improvement by over 1,000 hospitals in the U.S.
ABT: 44.09 (+0.72)
Global Coagulation Testing Market 2014-2018 - Increase in Prevalence of CVD
M2 - Thu Oct 30, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdcwwv/global) has announced the addition of the "Global Coagulation Testing Market 2014-2018" report to their offering. Coagulation tests help in measuring the clotting ability of blood. Clotting is the process of blood converting from liquid into gel form. Coagulation tests are performed to analyze clotting disorders such as hemorrhage and thrombosis. Coagulation tests include complete blood count, factor V assay, fibrinogen level, prothrombin time, platelet count, thrombin time, and bleeding time. Coagulation testing analyzers play a major role in improving patients' quality of life. An expansion of some of the economies in the APAC region is one of the main trends seen in this market. Governments in emerging countries are making efforts to improve healthcare infrastructure, which has benefited the Coagulation Testing market. According to the report, one of the major drivers in the market is the increase in the prevalence of cardiovascular disease. CVD deaths occur almost equally in men and women and it is predicted that by 2030 almost 23.6 million people will die from CVD. An increase in the prevalence of CVD has led to the development of coagulation testing products, and thus, the growth of the market. Further, the report states that one of the major challenges in the market is the high cost incurred in R&D activities. Many big vendors are facing the frequent elimination of coagulation testing analyzer products because of rapid developments with respect to the technological aspects of coagulation testing analyzers. The Global Coagulation Testing market can be segmented into the revenue generated from end- user application such as: - Point-of-Care Coagulation Testing - Home Diagnostics Key Vendors - Abbott Laboratories - Danaher - F. Hoffmann-La Roche - Sysmex Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Coagulation Testing Application - Market Landscape - Market Segmentation by Technology - Market Segmentation by Types Coagulation Tests - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/kdcwwv/global
ABT: 44.09 (+0.72), DHR: 81.29 (+0.10)
Abbott Labs Pays $250 Million for Topera in Heart Health Move
at The Street - Thu Oct 30, 8:12AM CDT
The buyer also acquired an option to purchase Advanced Cardiac Therapeutics, which is developing a novel ablation catheter.
ABT: 44.09 (+0.72), ACT: 245.73 (-0.18)
Abbott Expands Its Medical Device Business with Acquisition in Catheter-Based Electrophysiology Market
PR Newswire - Wed Oct 29, 8:30AM CDT
Abbott (NYSE: ABT) today announced that it has entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation, one of the most common heart rhythm disorders in the world. Through this acquisition, Abbott enters the catheter-based electrophysiology market, an approximately $3 billion global market that has been growing annually at double-digit rates.
ABT: 44.09 (+0.72)
The Zacks Analyst Blog Highlights:AbbVie, Mylan, Abbott Laboratories, Actavis and Mallinckrodt
PR Newswire - Wed Oct 29, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Mylan, Inc. (Nasdaq:MYL-Free Report), Abbott Laboratories (NYSE:ABT-Free Report), Actavis plc (NYSE:ACT-Free Report) and Mallinckrodt plc (NYSE:MNK-Free Report).
ABT: 44.09 (+0.72)
Upgrade Alert for Abbott Laboratories (ABT)
Comtex SmarTrend(R) - Wed Oct 29, 7:58AM CDT
Abbott Laboratories (NYSE:ABT) was upgraded from Hold to Buy at Deutsche Bank today. The stock closed yesterday at $42.50 on volume of 6.1 million shares, above average daily volume of 5.5 million. Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company's products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
ABT: 44.09 (+0.72)
